We are currently running R&D projects with an aim to develop medicinal products offering the optimal effectiveness and the safety of pharmacotherapy. We create a concept for the novel therapeutic solutions based on the combination of our pharmaceutical and pharmacological knowledge and experience in the design and development of dosage forms.
We focus on the development of solutions covering the needs of patients suffering from the civilisation diseases such as diabetes, hypertension, coronary artery disease, and the elderly population patients as well.
In our portfolio you can find the projects based on the unique combinations of the active substances and on the application of innovative technologies of pharmaceutical forms.
CARDIO project – innovative formulation of the combination drug used for hypertension
The aim of this project is to develop an innovative form and manufacturing technology for a three-component combination drug for hypertension therapy dedicated for patients requiring concurrent antiatherosclerotic prevention.
The project is conducted in the cooperation with the scientists of Poznań University of Medical Sciences and for this purpose, we received financing from the national funds within the TANGO IV C project.
HEART project – an innovative formulation of the combination drug used in the coronary artery disease therapy
The National Cardiology Institute defines the Coronary Artery Disease (CAD) as a medical condition characterised by an insufficient blood supply to the heart caused by a significant narrowing (and sometimes full occlusion) of the lumen of coronary arteries feeding the heart muscle. In most cases, coronary artery disease is atherosclerotic and very often occurs with Peripheral Artery Disease.
Coronary artery disease is the most common cardiovascular disease of people living in developed countries. Additionally, heart attack and sudden cardiac death are the most common mortality causes. The average annual incidence of coronary heart disease is approximately 250–300 new cases for 100,000 inhabitants.
The aim of the project is to develop an innovative form and technology to manufacture an oral combination drug dedicated for patients with stable coronary artery diseases and peripheral arterial disease for use in the prevention of ischemic complications. The therapeutic concept is based on the combination of two active substances used in the antithrombotic therapy of atherosclerotic diseases and is based on the results of breakthrough clinical trials which have shown that the additional inhibition of the selected levels of the coagulation cascade significantly influences the prevention of the cardiovascular events.
DIAMO project – an innovative formulation of an antidiabetic drug
World Health Organisation defines diabetes as a group of metabolic diseases characterised with hyperglycaemia resulting from insulin secretion or activity defect. Chronic hyperglycaemia in diabetes is associated with renal damage and dysfunction, and failure of various organs, especially eyes, kidneys, nerves, heart, and blood vessels.
Year by year, the problem of diabetes and its complications becomes more and more apparent, both from a medical and economical point of view. The statistics show that a constant increase in the incidence both in the developed countries and in the low- and middle-income countries as well. Diabetes is one of the four non-infectious diseases addressed in actions by world leaders and the scale of the problem is so significant that we can describe it as a pandemic.
The aim of the project is to develop an innovative medicinal product formulation containing an amorphous active substance form in polymer-API setting ensuring appropriate effectiveness of the pharmacotherapy. One of the key elements of the project is to develop and optimise the active substance amorphisation process which is conducted using the hot melt extrusion technique. The developed formulation prototype is characterised by the high stability of the amorphic form and the release profile analogous to the originator.
We received the financing from the European Funds within the Regional Operation Programme for Greater Poland 2014–2020.
PAIN Project – an innovative formula of a combination analgesic drug
The aim of this project is to develop and innovative form and manufacturing technology of the combination oral analgesic drug. The bi-functional preparation combines the active substances with various mechanisms of action and their biological half-life is suitable for the once-a-day administration. The innovative preparation will simplify the drug administration algorithms and will be particularly helpful in the pain therapy of elderly patients.
The project is conducted in the cooperation with the scientists of Poznań University of Medical Sciences and for this purpose, we received financing from the national funds within the Smart Growth Operational Program.